Table 3.
Baseline clinical data and modified clot lysis assay (mCLA)* parameters according to mortality by day 14.
|
Survival by day 14 (n = 63) |
Non-survival by day 14 (n = 26) | p | |
|---|---|---|---|
| Age, y, mean ± SD | 67 ± 12 | 71 ± 10 | 0.082 |
| Male sex, n (%) | 29 (46) | 10 (39) | 0.474 |
| Stroke severity on admission, NIHSS, median (IQR) | 11 (5–17) | 19 (16–23) | <0.0001 |
| Cerebrovascular risk factors, n (%) | |||
| Arterial hypertension | 59 (94) | 26 (100) | 0.552 |
| Atrial fibrillation | 7 (11) | 3 (12) | 0.999 |
| Diabetes mellitus | 24 (38) | 14 (54) | 0.191 |
| Hyperlipidemia | 34 (54) | 14 (54) | 0.932 |
| Active smoker | 14 (22) | 2 (8) | 0.032 |
| BMI, kg/m2, median (IQR) | 27.1 (23.3–32.4) | 26.9 (25.4–30.6) | 0.810 |
| Laboratory measurements on admission, median (IQR) | |||
| INR | 0.96 (0.93–1.00) | 1.02 (0.96–1.68) | 0.009 |
| APTT, s | 27.7 (25.4–30.1) | 28.3 (25.1–36.5) | 0.430 |
| WBC, G/L | 8.6 (6.5-11.2) | 9.3 (6.9-12.0) | 0.538 |
| Platelet count, G/L | 238 (172–283) | 203 (167–242) | 0.049 |
| Serum glucose, mmol/L | 7.3 (5.8–9.7) | 8.2 (6.5–11.4) | 0.094 |
| hsCRP, mg/L | 3.2 (1.2–7.1) | 2.4 (1.3–3.8) | 0.373 |
| Creatinine, μmol/L | 69 (60-82) | 76 (62-95) | 0.326 |
| Fibrinogen, mg/ml | 4.0 (3.2–4.6) | 3.4 (2.9–4.2) | 0.086 |
| Plasminogen activity (%) | 112 (97-123) | 107 (103-114) | 0.212 |
| α2- plasmin inhibitor activity (%) |
107 (99–113) | 105 (94–114) | 0.422 |
| Factor XIII activity (%) | 167 (147–175) | 161.5 (132–177) | 0.414 |
| mCLA parameters | |||
| Maximal absorbance (OD) | 1.48 ± 0.25 | 1.41 ± 0.21 | 0.374 |
| Time to maximal absorbance (min) | 11.5 (8.0–15.0) | 10.0 (8.0–14.0) | 0.724 |
| 10%CLT (min) | 30.0 (22.0–37.5) | 20.5 (18.0–30.0) | 0.037 |
| 50%CLT (min) | 39.0 (28.0–51.0) | 34.0 (27.5–45.5) | 0.491 |
| 90%CLT (min) | 76.5 (69.0–87.0) | 74.0 (61.0–82.5) | 0.179 |
| CLA AUC (OD*min) | 25.6 (19.8–31.5) | 24.1 (20.3–28.5) | 0.459 |
*
mCLA is performed in the presence of cell-free DNA and histones. Data are means ± SD or medians (interquartile ranges). 10%CLT, 10% clot lysis time; 50%CLT, 50% clot lysis time; 90%CLT, 90% clot lysis time; CLA, clot lysis assay; CLA AUC, clot lysis assay area under the curve; APTT, activated partial thromboplastin time; BMI, body mass index; hsCRP, high sensitivity C-reactive protein measurement; INR, international normalized ratio.